Johnson & Johnson (JNJ)vsOmada Health, Inc. Common Stock (OMDA)
JNJ
Johnson & Johnson
$221.32
-0.53%
HEALTHCARE · Cap: $535.63B
OMDA
Omada Health, Inc. Common Stock
$14.82
-9.63%
HEALTHCARE · Cap: $974.41M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 36932% more annual revenue ($96.36B vs $260.21M). JNJ leads profitability with a 21.8% profit margin vs -4.9%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
OMDA
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-37.5%
Fair Value
$160.99
Current Price
$221.32
$60.33 premium
Margin of Safety
+41.8%
Fair Value
$18.79
Current Price
$14.82
$3.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Revenue surging 58.1% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 4.3%
ROE of -8.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : OMDA
The strongest argument for OMDA centers on Revenue Growth. Revenue growth of 58.1% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : OMDA
The primary concerns for OMDA are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while OMDA is a hypergrowth play — different risk/reward profiles.
OMDA is growing revenue faster at 58.1% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
JNJ scores higher overall (59/100 vs 37/100), backed by strong 21.8% margins. OMDA offers better value entry with a 41.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Omada Health, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?